Mirtazapine Aurobindo

Mirtazapine, the active ingredient in Mirtazapine Aurobindo, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for oral use. It is prescribed to treat major depressive disorder in adult patients, helping to improve mood, sleep and appetite, and is often selected when other antidepressants have been insufficient.

GNH USA supplies Mirtazapine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for global markets and ensuring product integrity throughout the supply chain.

Mirtazapine is a NaSSA‑type antidepressant that modulates noradrenergic and serotonergic pathways to treat depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. - Treatment‑resistant depression: may be added when first‑line antidepressants have not achieved adequate response. - Depression with insomnia: helps alleviate sleep disturbances associated with depressive episodes.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Serotonin syndrome, especially with other serotonergic drugs - Severe hypotension or syncope - Seizures - Suicidal thoughts or worsening depression - Hepatotoxicity (rare)

Before initiating therapy, clinicians should evaluate several safety considerations.

- Assess hepatic function: adjust dose or avoid use in severe liver impairment. - Monitor body weight: anticipate possible weight gain and counsel on nutrition. - Screen for suicidal ideation: particularly during the first weeks of treatment. - Use caution in elderly patients: increased risk of sedation, falls and orthostatic hypotension. - Avoid abrupt discontinuation: taper the dose to reduce withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, and some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increase risk of serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): raise mirtazapine plasma concentrations. - Alcohol: may enhance sedative effects and impair cognition.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive hypotensive effect. - Anticholinergic medications: may exacerbate anticholinergic burden. - Carbamazepine or other enzyme inducers: may reduce mirtazapine effectiveness. - Lithium: monitor for increased sedation. - Oral contraceptives: possible alteration of hormone levels, monitor efficacy.